Skip to main content
. 2013 Sep;57(9):4134–4138. doi: 10.1128/AAC.00461-13

Fig 2.

Fig 2

Emergence of resistance during drug administration. (A) Negative control (no treatment) and active controls (ceftolozane at 375 mg every 8 h [Q8h] and piperacillin [PIP]-tazobactam at 4.5 g every 6 h). (B) Ceftolozane-tazobactam (TOL/TAZ) dosing regimens ranging from 125-62.5 to 1,500-750 mg infused every 8 h.